Group One Trading, L.P. Cytom X Therapeutics, Inc. Transaction History

Group One Trading, L.P.

$2.4 Billion
Q3 2024

A detailed history of Group One Trading, L.P. transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 4,911 shares of CTMX stock, worth $5,352. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,911

Previous 16,964 71.05%

Holding current value

$5,352

Previous $20,000 75.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.12 - $1.51 $13,499 - $18,200	-12,053 Reduced 71.05%	4,911 $5,000
Q2 2024 Aug 14, 2024	BUY	$1.21 - $5.13 $19,755 - $83,757	16,327 Added 2563.11%	16,964 $20,000
Q3 2023 Nov 09, 2023	SELL	$1.26 - $1.87 $3,777 - $5,606	-2,998 Reduced 82.48%	637 $0
Q2 2023 Aug 09, 2023	BUY	$1.41 - $1.92 $3,525 - $4,800	2,500 Added 220.26%	3,635 $6,000
Q1 2023 May 12, 2023	BUY	$1.48 - $2.88 $1,389 - $2,704	939 Added 479.08%	1,135 $1,000
Q2 2022 Aug 11, 2022	SELL	$1.53 - $2.89 $459 - $867	-300 Reduced 60.48%	196 $0
Q1 2022 May 12, 2022	SELL	$2.67 - $4.68 $2,710 - $4,750	-1,015 Reduced 67.17%	496 $1,000
Q4 2021 Feb 11, 2022	BUY	$3.87 - $7.39 $5,847 - $11,166	1,511 New	1,511 $7,000
Q3 2021 Nov 12, 2021	SELL	$4.32 - $6.43 $7,776 - $11,574	-1,800 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$6.33 - $9.91 $4,431 - $6,937	700 Added 63.64%	1,800 $11,000
Q1 2021 May 12, 2021	BUY	$6.6 - $9.0 $7,260 - $9,900	1,100 New	1,100 $9,000
Q1 2018 May 11, 2018	SELL	$21.76 - $34.22 $6,528 - $10,266	-300 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$19.0 - $23.09 $5,700 - $6,927	300	300 $6,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

50.7M

Call Options Held

112K

Put Options Held

8.3K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $71.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Account

Group One Trading, L.P. Cytom X Therapeutics, Inc. Transaction History